Treatment of metastatic squamous cell carcinoma arising in sacrococcygeal pilonidal sinus : a case report series
Copyright © 2023 Soria Rivas, Bea-Ardebol, Vida Navas, Muñoz-Arrones, Cabañas-Montero, Mena-Mateos, López-Campos, Corral Moreno, Pérez-Muñoz, González Lizan, Sanz Pascual and Serrano Domingo..
Background: Squamous cell carcinoma (SCC) arising in a sacrococcygeal pilonidal sinus is rare, with cases of metastatic disease being even rarer. Among published cases, almost none have reported on systemic treatment.
Objective: This disease has a poorer prognosis than other forms of cutaneous SCC; therefore, our objective is to shed some light on the treatment of metastatic disease.
Methods: We present a series of nine cases treated at a single center, four of whom received systemic treatment. Additionally, other previously reported cases of metastatic disease are included in an attempt to draw stronger conclusions.
Results: Four patients were treated under several treatment regimens, with a median progression-free survival of only 2 months and two instances of partial response (18%). The best result was achieved with cemiplimab. Across all the cases, there was a trend toward a benefit of the use of systemic treatment (HR 0.41, 95% CI 0.15-1.12, p = 0.083; median overall survival 13 vs. 8 months).
Limitations: Limitations include the significant lack of information on previously published cases and the extremely heterogeneous nature of the existing information.
Conclusion: The initial systemic treatment should be an anti-PD-1, as with other SCCs. After progression on anti-PD-1, there is no strong evidence to support the recommendation of a specific treatment or sequence: options include cetuximab and/or chemotherapy (platinum, paclitaxel, 5-fluorouracyl).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Frontiers in medicine - 10(2023) vom: 27., Seite 1248894 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Soria Rivas, Ainara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-PD-1 |
|---|
| Anmerkungen: |
Date Revised 03.10.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fmed.2023.1248894 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362764190 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362764190 | ||
| 003 | DE-627 | ||
| 005 | 20231226091924.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fmed.2023.1248894 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362764190 | ||
| 035 | |a (NLM)37780565 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Soria Rivas, Ainara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of metastatic squamous cell carcinoma arising in sacrococcygeal pilonidal sinus |b a case report series |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.10.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 Soria Rivas, Bea-Ardebol, Vida Navas, Muñoz-Arrones, Cabañas-Montero, Mena-Mateos, López-Campos, Corral Moreno, Pérez-Muñoz, González Lizan, Sanz Pascual and Serrano Domingo. | ||
| 520 | |a Background: Squamous cell carcinoma (SCC) arising in a sacrococcygeal pilonidal sinus is rare, with cases of metastatic disease being even rarer. Among published cases, almost none have reported on systemic treatment | ||
| 520 | |a Objective: This disease has a poorer prognosis than other forms of cutaneous SCC; therefore, our objective is to shed some light on the treatment of metastatic disease | ||
| 520 | |a Methods: We present a series of nine cases treated at a single center, four of whom received systemic treatment. Additionally, other previously reported cases of metastatic disease are included in an attempt to draw stronger conclusions | ||
| 520 | |a Results: Four patients were treated under several treatment regimens, with a median progression-free survival of only 2 months and two instances of partial response (18%). The best result was achieved with cemiplimab. Across all the cases, there was a trend toward a benefit of the use of systemic treatment (HR 0.41, 95% CI 0.15-1.12, p = 0.083; median overall survival 13 vs. 8 months) | ||
| 520 | |a Limitations: Limitations include the significant lack of information on previously published cases and the extremely heterogeneous nature of the existing information | ||
| 520 | |a Conclusion: The initial systemic treatment should be an anti-PD-1, as with other SCCs. After progression on anti-PD-1, there is no strong evidence to support the recommendation of a specific treatment or sequence: options include cetuximab and/or chemotherapy (platinum, paclitaxel, 5-fluorouracyl) | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a anti-PD-1 | |
| 650 | 4 | |a case report | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a metastatic | |
| 650 | 4 | |a pilonidal sinus | |
| 650 | 4 | |a squamous cell carcinoma | |
| 700 | 1 | |a Bea-Ardebol, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Vida Navas, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz-Arrones, Óscar M |e verfasserin |4 aut | |
| 700 | 1 | |a Cabañas-Montero, Luis Jacobo |e verfasserin |4 aut | |
| 700 | 1 | |a Mena-Mateos, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a López-Campos, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Corral Moreno, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Muñoz, Israel |e verfasserin |4 aut | |
| 700 | 1 | |a González Lizan, Fausto |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz Pascual, María |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano Domingo, Juan Jose |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in medicine |d 2014 |g 10(2023) vom: 27., Seite 1248894 |w (DE-627)NLM245390847 |x 2296-858X |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g day:27 |g pages:1248894 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fmed.2023.1248894 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |b 27 |h 1248894 | ||